Wall Street brokerages expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to announce earnings per share (EPS) of ($0.47) for the current quarter, Zacks reports. Five analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.38). Syros Pharmaceuticals reported earnings of ($0.54) per share during the same quarter last year, which indicates a positive year over year growth rate of 13%. The firm is scheduled to report its next earnings report on Thursday, March 5th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.89) per share for the current year, with EPS estimates ranging from ($2.01) to ($1.77). For the next financial year, analysts forecast that the company will report earnings of ($1.94) per share, with EPS estimates ranging from ($2.38) to ($1.56). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.01. The business had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%.
In other news, insider Jeremy P. Springhorn bought 9,879 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was purchased at an average price of $4.99 per share, with a total value of $49,296.21. Following the transaction, the insider now owns 24,879 shares of the company’s stock, valued at $124,146.21. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 14.80% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Syros Pharmaceuticals by 191.6% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,633,773 shares of the company’s stock worth $48,099,000 after buying an additional 3,044,728 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its stake in shares of Syros Pharmaceuticals by 336.5% in the second quarter. Nikko Asset Management Americas Inc. now owns 2,987,763 shares of the company’s stock worth $27,667,000 after acquiring an additional 2,303,288 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Syros Pharmaceuticals by 95.7% in the second quarter. Vanguard Group Inc. now owns 1,765,010 shares of the company’s stock worth $16,344,000 after acquiring an additional 863,074 shares during the last quarter. ARK Investment Management LLC increased its position in shares of Syros Pharmaceuticals by 26.7% during the second quarter. ARK Investment Management LLC now owns 3,791,756 shares of the company’s stock worth $35,112,000 after purchasing an additional 799,056 shares in the last quarter. Finally, Samsara BioCapital LLC increased its position in shares of Syros Pharmaceuticals by 62.9% during the second quarter. Samsara BioCapital LLC now owns 1,726,603 shares of the company’s stock worth $15,228,000 after purchasing an additional 666,665 shares in the last quarter.
SYRS opened at $4.78 on Friday. The business has a 50 day simple moving average of $5.51 and a two-hundred day simple moving average of $7.76. The firm has a market capitalization of $216.45 million, a price-to-earnings ratio of -2.50 and a beta of 1.47. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.92 and a quick ratio of 4.92. Syros Pharmaceuticals has a one year low of $4.53 and a one year high of $11.93.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
See Also: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.